drugset / Trial / NCT02173249
A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the Plasma Pharmacokinetics and Safety of AC 170 0.24% in Healthy, Adult Subjects when used twice daily for one week.
Timeline
- Start
- 2014-06
- Primary completion
- 2014-08
- Completion
- 2014-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetirizine | Other / unclassified | 0.24 % | Other |
Indications
No indication recorded.